VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Bio-Rad Laboratories, Inc. vs Pfizer Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Bio-Rad Laboratories, Inc.
BIO · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bio-Rad Laboratories, Inc.'s moat claims, evidence, and risks.
View BIO analysisPfizer Inc.
PFE · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Comparison highlights
- Moat score gap: Bio-Rad Laboratories, Inc. leads (61 / 100 vs 58 / 100 for Pfizer Inc.).
- Segment focus: Bio-Rad Laboratories, Inc. has 2 segments (59.9% in Clinical Diagnostics); Pfizer Inc. has 5 segments (47.4% in Primary Care).
- Moat breadth: Bio-Rad Laboratories, Inc. has 6 moat types across 3 domains; Pfizer Inc. has 8 across 3.
Primary market context
Bio-Rad Laboratories, Inc.
Clinical Diagnostics
In vitro diagnostics test systems, reagents/test kits, informatics, and clinical laboratory quality controls
Global
Hospital laboratories; diagnostic reference laboratories; transfusion laboratories; physician office laboratories
IVD OEM / installed-base consumables supplier (systems + kits + controls)
59.9%
Pfizer Inc.
Primary Care
Branded primary care medicines and vaccines (incl. cardiovascular, migraine, pneumococcal/RSV/COVID-19)
Global
Healthcare providers, payers/PBMs, pharmacies/wholesalers, and government procurement
Innovator biopharma (R&D + manufacturing + commercialization)
47.4%
Side-by-side metrics
Moat coverage
Shared moat types
Bio-Rad Laboratories, Inc. strengths
Pfizer Inc. strengths
Segment mix
Bio-Rad Laboratories, Inc. segments
Full profile >Life Science
Competitive
Clinical Diagnostics
Oligopoly
Pfizer Inc. segments
Full profile >Primary Care
Oligopoly
Specialty Care
Oligopoly
Oncology
Competitive
Pfizer CentreOne
Competitive
Pfizer Ignite
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.